Cigna has agreed to cover Interpace Diagnostics' ThyGenX molecular thyroid test, a next-generation sequencing test that identifies over 100 papillary and follicular thyroid carcinoma-related genetic alterations. The coverage, which takes effect immediately, makes the test available to around 15 million Cigna plan members nationwide.
Interpace's molecular thyroid test scores reimbursement win
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.